Viva Biotech Holdings · HKEX:1873
Viva Biotech — H1 2022 Earnings Presentation
27 slides from Viva Biotech's earnings presentation, Aug 30, 2022
Slide 1: Viva Biotech 2022 Interim Results
Viva Biotech 2022 Interim Results August 30, 2022 Shanghai, China
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
CP iva PART 1: Business Highlights
Slide 5: World Leading One-stop Drug Research and Production Platform
World Leading One-stop Drug Research and Production Platform CRO Business CDMO Research and Production EFS Investment & Business Incubation Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core to drive FBDD, d
Slide 6: Continued to Build Technology Barriers, Improved CRO-CDMO Service Capabilities
Continued to Build Technology Barriers, Improved CRO-CDMO Service Capabilities as a One-stop Platform SBDD FBDD Compound design Viva Fragment Library Viva Compound CADD R&D expenses were approximately RMB40.9 Library Computational Chemistry & million in 2022 1H, representing an increase ASMS scree
Slide 7: Overview Business Highlights
Overview Business Highlights 2022 H1 revenue: RMB1108.7 million, + 8.0% YOY Gross profit: RMB345.0 million, +9.1% YOY Adjusted net profit: RMB89.0 million, -54.8% YOY Adjusted basic earnings per share: RMB0.04 2104 The Group’s total no. of clients: 1947, widely located in North America, Eu
Slide 8: Overview: CRO
Overview CRO：The Core Competitiveness Remained Ahead with Favorable Backlog in the Medium and Long Term Despite the Growth Rate was Affected by the Fluctuations of COVID-19 in 2022 1H 85.8 CFS EFS Revenue: RMB406 million, +26.48% YOY Gross profit: RMB179.0 million, +26.1% YOY Revenue from Top
Slide 9: CRO: Maintained Growth in Clients and R&D Staff with Favorable Backlog
CRO: Maintained Growth in the No. of Clients and R&D Staff with Favorable Backlog Order backlog: +35.61% YOY No. of CRO R&D staff: +37.9% YOY RMB million 1354 1150 1211 965 982 848 2021H1 2021 2022H1 2021H1 2021 2022H1 Served Top 10 global pharmaceutical companies No. of CRO clients: +18.7% YOY 2022
Slide 10: CRO: Expanding Scale with Targets and Protein Structures Delivered
CRO: Expanding Scale with No. of Targets and Protein Structures Delivered Hit Record High Radiation source usage No. of targets and protein structures delivered Hours 2022H1 962 Independent targets: +47 2021 1934 2021H1 822 Cumulative Number: 1857 Maintained Long-term cooperation with 12 synch
Slide 11: Overview Langhua Pharmaceutical R&D and Production Services
Overview Langhua Pharmaceutical R&D and Production Services Langhua’s revenue: RMB703 million, -0.4% YOY Langhua’s adjusted gross profit: RMB173 million, -10.36% YOY 111 CDMO: revenue RMB397 million, -18.81% YOY; gross profit margin 32.7%, 140 -2.06pp YOY 105 Intermediates and 166 formulation
Slide 12: CDMO: Affected by Delivery Delay in Short Term, Medium and Long-term Growth Remained
CDMO: Affected by the Delivery Delay in the Short Term, but the Medium and Long- term Growth Remained the Same with Favorable Backlog Revenue and gross profit from CDMO Production capacity expansion plan (21-23E) Cubic meter RMB million 489 Revenue 2024E 1260 397 Gross profit 2023E 860 170 130 2022E
Slide 13: Continued to Strengthen CMC Capacity Building
Continued to Strengthen CMC Capacity Building Revenue scale CMC staff 2022H1 150 ～RMB11 million 2021 120 2022H1 2022E Internal and external two-pronged approach for CMC diversion 2022 H1 Revenue of CMC: approx. RMB11 million, not yet achieved breakeven Viva’s diversion affected by COVID-19 Externa
Slide 14: Overview EFS Investment & Incubation Business
Overview EFS Investment & Incubation Business RMB million Completed 9 investments in 2022 H1, of which 3 were newly-added 1519 1419 As of Jun 30, 2022, invested in a total of 90 portfolio companies In July 2022, one portfolio company achieved a partial exit through equity transfer, with an 125
Slide 15: VBI Portfolio Companies Overview
VBI Portfolio Companies Overview As of 2022 H1, VBI invested in a total of 90 projects. And VBI reviewed 363 projects, added 3 start-ups to portfolio companies, made new investments in 2 funds and made additional investments in 4 existing portfolio companies in 2022 1H In July 2022, one portfoli
Slide 16: High-speed Pipeline Expansion & Smooth Progress in Financing
High-speed Pipeline Expansion & Smooth Progress in Financing 199 product pipelines for portfolio companies • ANJ900 entered phase III clinical trial; ANJ908 2021H1 entered phase II clinical 199 trial 2022H1 121 • VVN001 published the results of phase II clinical trial; VVN539 entered phase II 140 cl
Slide 17: Part 2: Financial Performance
PART 2: Financial Performance
Slide 18: Financial Performance of the Group
Financial Performance of the Group Maintained Growth in Revenue RMB million RMB million Maintained Growth in Gross Profit Increased 8.0% Increased 9.1% 1108.7 1026.5 316.2 345 2021H1 2022H1 2021H1 2022H1 Adjusted Net Profit Adjusted EBITDA RMB million Decreased 54.8% 297 196.9 Decreased 36.7% 188 89
Slide 19: CRO BU Financial Statistics
CRO BU Financial Statistics CRO revenue RMB million RMB million CRO gross profit Increased 26.48% 406 Increased 26.1% 321 179 142 2021H1 2022H1 2021H1 2022H1 No.of CRO R&D staff Annual revenue per CRO Personnel RMB’000 Increased 48.2% Decreased 8.3% 1354 982 653 599 2021H1 2022H1 19 2021H1 2022H1
Slide 20: CDMO BU Financial Statistics
CDMO BU Financial Statistics Langhua's revenue RMB million Langhua’s adjusted gross profit RMB million Decreased 0.4% Decreased 10.36% 705 703 193 173 2021H1 2022H1 2021H1 2022H1 20
Slide 21: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities For the six months ended 30 June 2022 Drug discovery service CDMO and commercialization service Total Types of goods or services RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) services 302,739 - 302,739 Fee-for-service (F
Slide 22: Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss
Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows: RMB’000 At January 1, 2022 (audited) 1,246,730 Acquired 50,406 Recognized from SFE revenue 27,169 Gain on fair
Slide 23: Part 3: Future Strategies
CP iva PART 3: Future Strategics
Slide 24: Improve Capacity Building for Front-end Projects and Expand the Whole Industry Chain
Improve Capacity Building for Front-end Projects and Continue to Expand the Whole Industry Chain Service Downstream To establish an open and cooperative Early-stage pre-clinical CFS CFS EFS EFS platform and a win-win ecosystem for service global biopharmaceutical innovators Raise technology barrie
Slide 25: Q&A session
CP iva Q&A session
Slide 26: Thank You!
Thank You! Ir@vivabiotech.com
Slide 27: Appendix: Adjusted Non-IFRS Net Profit
Appendix: Adjusted Non-IFRS Net Profit 2022H1 2021 2021H1 2020 RMB’000 RMB’000 RMB’000 RMB’000 Net profit / (loss) (85,220) 300,560 95,802 -378,870 Add: fair value (gain) loss on financial liabilities at FVTPL (10,050) (143,590) 13,366 547,048 Add: interest expenses of the debt components of the 67,
Viva Biotech Holdings — H1 2022 Earnings Presentation on 6ix